Abstract: A method for the discovery of compounds suitable for the treatment and/or prophylaxis of obesity, in which the ability of the test compounds to inhibit de novo lipogenesis in mammals and/or man is determined. The use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the CNS, for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of obesity, as well as for the treatment and/or inhibition of obesity, are also described.

Abstract: A method for the discovery of compounds suitable for the treatment and/or prophylaxis of obesity, in which the ability of the test compounds to inhibit de novo lipogenesis in mammals and/or man is determined. The use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the CNS, for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of obesity, as well as for the treatment and/or inhibition of obesity, are also described.

Abstract: Compounds having combined, particularly concurrent, inhibitory activity on neutral endopeptidase (NEP) and on a novel metalloprotease designated IGS5, or of a pharmaceutically acceptable salt or solvate or biolabile ester thereof, and related methods for treating and for the manufacture of a pharmaceutical composition for a mammal, preferably a larger mammal such as a human, suffering from or being susceptible to a disease or condition which can be alleviated or inhibited by combined or concurrent inhibition of NEP and IGS5. Treatments for diseases or conditions where big-ET-1 levels are elevated, or where ET-1 is upregulated, where such diseases or conditions can be alleviated or inhibited by combined or concurrent inhibition of NEP and IGS5.

Abstract: 4-substituted 1-amidomethylcarbonyl-piperidine compounds having motilin-agonistic properties and their acid addition salts, pharmaceutical compositions containing these compounds, processes and intermediate products for the preparation of these compounds, and methods of treatment utilizing these compounds.

Abstract: The present invention relates to the use of 3,7-diazabicyclo[3,3,1]nonane compounds, preferably of 9,9-alkylene-3,7-diazabicyclo[3,3,1]nonane compounds, and most preferably to the use of tedisamil, and the physiologically acceptable acid addition salts and/or solvates thereof, in the form of a liquid pharmaceutical preparation for the treatment and/or inhibition of anti-arrhythmic events in human patients, preferably in conversion of recent onset of atrial fibrillation or flutter to normal sinus rhythm in humans. Furthermore, the invention concerns related methods of treatment and pharmaceutical products.

Abstract: Novel 1-[1-(hetero)aryl-1-perhydroxyalkylmethyl]-piperazine compounds which are antagonistic to tachykinin receptors, of the general formula I, wherein R6, R7, A and Z have the meanings given in the description, and pharmaceutical compositions containing these compounds, as well as a process for the preparation of such compounds and intermediate products of this process.

Abstract: A method of preventing or inhibiting subsequent strokes by administering an AT1-receptor antagonist, in particular eprosartan, to a patient who has previously suffered a first stroke.

Abstract: A method for obtaining an extract containing the natural mixture of conjugated equine estrogens by liquid-liquid extraction of the mixture of conjugated equine estrogens, wherein the mixture obtained is depleted in non-conjugated lipophilic compounds selected from the group consisting of non-conjugated flavonoids, non-conjugated isoflavonoids, non-conjugated norisoprenoids, non-conjugated steroids, in particular androstane and pregnane steroids, and comparable non-conjugated compounds.

Abstract: Mixtures of microbial enzymes containing a concentrated Rhizopus delemar lipase, an Aspergillus melleus protease and an Aspergillus oryzae amylase; pharmaceutical preparations containing such mixtures; and the use of such mixtures in methods of treatment and/or prophylaxis of maldigestion, especially maldigestion caused by pancreatic insufficiency, in humans or other mammals.

Abstract: A urine collecting device for horses, especially mares, suitable for attachment to a special holding harness and a special head part therefor, which is advantageously suitable for collecting pregnant mares' urine for obtaining natural mixtures of conjugated estrogens. The holding harness with urine collecting device according to the invention offers high flexibility and wearing comfort for the horse. The horse's freedom of movement is not substantially impaired by the holding harness with urine collecting device, so grazing is possible, and it is not necessary to tether the horse in a narrow stall. The urine collecting device of the invention is distinguished in particular in that the urine collecting part and the head part are joined via a detachable connection, such as a bayonet lock.

Abstract: A method of producing alkanes containing chlorine by addition of chlorine to C—C double bonds or C—C triple bonds or by exchange of hydrogen for chlorine by contacting the starting compound in the gas or liquid phase with elemental chlorine and irradiating the reaction mixture with UV tight having a wavelength of &lgr;≧280 nm. In this way pentachloroethane can be produced from trichloroethylene, CFC-113 from HCFC-123 or HFC-133a, CFC-112a from HCFC-142b, or HCFC-123 from HCFC-133a. The method also is suitable for separating photochlorinatable impurities from HFC-365-mfc to obtain purified HFC-365-mfc. Advantages include high yields and excellent selectivity.

Abstract: A holding harness with a urine collecting device for horses, as well as a urine collecting device suitable for the holding harness and a special head part for such a urine collecting device, which is advantageously suitable for collecting urine from pregnant mares for obtaining natural mixtures of conjugated estrogens. The holding harness according to the invention with urine collecting device offers high flexibility and comfort of wear for the horse. The freedom of movement of the horse is not significantly impaired by the holding harness with urine collecting device, so that grazing is possible and it is unnecessary to tether the horse in a narrow stall.

Abstract: A method of separating cresol from mares' urine by pervaporation using pore-free polymeric silicone membranes in which starting urine solutions containing high-quality and -quantity conjugated estrogens with a reduced or substantially removed cresol content are provided which are advantageously suitable for obtaining natural mixtures of conjugated estrogens from pregnant mares' urine.

Abstract: Components composed of aluminum or an aluminum alloy with a coating comprising an aluminum-silicon alloy deposited thereon by applying an alkali metal fluorosilicate and heating the resulting treated material. The alloy layer is effectively protected against re-oxidation by a non-corrosive, alkali metal fluoroaluminate layer (e.g. a potassium fluoroaluminate layer) which forms simultaneously.

Abstract: Pharmacologically active compounds of the general formula I wherein R1 is an alkyl group with 1-6 carbon atoms or a cycloalkylalkyl group with 4-7 carbon atoms, R2 is lower alkyl, and R3 is lower alkyl, or R2 and R3 together form an alkylene chain with 3-6 carbon atoms, and R4 represents a phenyl radical monosubstituted in the ortho or para position by nitro, cyano or lower alkanoyl or disubstituted in the ortho and para positions by nitro, and their physiologically compatible acid addition salts are described.

Abstract: The present invention relates to the use of cilansetron for the treatment of non-obstipative male IBS patients.

Abstract: Novel 1-[1-(hetero)aryl-1-perhydroxyalkylmethyl]-piperazine compounds which are antagonistic to tachykinin receptors, of the general formula I, 1

Abstract: Pharmacologically active compounds of the general formula I 1

Abstract: A method and apparatus for concentrating and stabilizing conjugated estrogens from pregnant mare urine on solid adsorbent supports to obtain a starting material for pharmaceuticals that contain a natural mixture of conjugated estrogens as active ingredient. The apparatus is suitable for decentralized concentration and stabilization of conjugated estrogen mixtures on cartridges in the vicinity of the horses. The adsorber cartridges can be loaded at the site of urine collection so it is unnecessary to transport large volumes of urine to a central processing point. The loading process can take continuously over a period of weeks until the column is saturated. The effluent urine remains at the site where facilities for its disposal are available. Only the loaded cartridge is transported, and transport can occur at longer intervals of up to several weeks. The stability of the conjugated estrogens on the adsorber assures there is no risk of decomposition.

Abstract: The present invention relates to the use of cilansetron for the treatment of non-obstipative male IBS patients.